J&J Talc Settlement
Johnson & Johnson proposes $5.5 billion settlement to end its decade-long talc lawsuit battle
Anonymous
Johnson & Johnson has proposed a $5.5 billion settlement to resolve remaining lawsuits claiming its talc products caused ovarian cancer, according to WTVR. The company's shares jumped more than 2% before markets opened on Tuesday.
The proposal caps a legal battle stretching more than a decade. The deal will only move forward if at least 95% of remaining claimants agree to participate, KJRH reported.
A Rejected $9 Billion Deal Paved the Way
This is not J&J's first attempt to close out its talc liability. A U.S. bankruptcy court judge rejected a prior $9 billion settlement last year, according to KTNV. That deal was proposed by a J&J subsidiary called Red River Talc. Had it passed, it would have been one of the largest mass tort settlements in U.S. history.
Mass tort settlements resolve claims from large groups of people who say they were harmed by the same product or company. J&J is now back with a smaller $5.5 billion offer, hoping enough claimants accept it to finally put the matter to rest, Fox 13 reported.
Talc Lawsuits Have Dogged J&J for Years
Johnson & Johnson has been fighting talc-related lawsuits for over a decade. The cases center on claims that its talcum powder products, including its iconic baby powder, contained harmful substances linked to ovarian cancer, according to 10 News.
The company has already settled roughly 95% of the approximately 95 mesothelioma lawsuits it faced. It also resolved all state consumer protection claims and all disputes with talc suppliers, WKBW reported. The remaining ovarian cancer cases are the last major piece of outstanding litigation.
The 95% Threshold Is the Key Hurdle
The $5.5 billion deal comes with a critical condition. At least 95% of the remaining claimants must agree to join the settlement. If that threshold is not met, the deal falls apart, according to KOAA.
Getting that level of buy-in from plaintiffs can be difficult. Lawyers representing cancer patients often advise clients to hold out for higher individual payouts. Whether J&J can clear the 95% bar will determine if this decade-long legal fight finally ends, KXXV reported.
Investors React Positively to Settlement Bid
Wall Street welcomed the news. J&J shares rose more than 2% in premarket trading on Tuesday, according to KIVI TV. Investors tend to reward companies that clear major legal uncertainty off their books.
Resolving the talc lawsuits would remove a long-running drag on J&J's stock and reputation. The company has maintained that its products were safe, but the years of litigation have cost it billions in legal fees and settlements, WTXL reported.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
9
Reach
10
A
AnonymousAuthor
